13 Sep 2013

Therapeutic Options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) – possible lessons from a systematic review of SARS-CoV therapy (Intl J Infect Dis., abstract, edited)

[Source: International Journal of Infectious Diseases, full page: (LINK). Abstract, edited.]

International Journal of Infectious Diseases, Volume 17, Issue 10, Pages e792-e798, October 2013

Therapeutic Options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) – possible lessons from a systematic review of SARS-CoV therapy

Hisham Momattin, Khurram Mohammed, Alimuddin Zumla, Ziad A. Memish, Jaffar A. Al-Tawfiq

Corresponding author. P.O. Box 76, Room A-428-2, Building 61, Dhahran Health Center, Saudi Aramco, Dhahran 31311, Saudi Arabia. Tel.: +966 3 877 3524; fax: +966 3 877 3790. published online 03 September 2013.

Corresponding Editor: Eskild Petersen, MD, DMSc, MBA, Editor-in-Chief, International Journal of Infectious Diseases

 

Abstract

The Middle East Respiratory Syndrome coronavirus (MERS-CoV) has been detected in a number of countries in the Middle East and Europe with an apparently high mortality rate. It is phylogenetically related to the SARS coronavirus and has also been associated with severe respiratory illness as well as nosocomial transmission in healthcare settings. Current international recommendations do not support any specific therapies; however, there are a number of agents, which were used during the SARS epidemic of 2003. It is possible that these might be active against the related MERS coronavirus. We have reviewed the literature on the safety and efficacy of therapies used in patients with SARS with a view to their potential use in patients with MERS-CoV infections.

PII: S1201-9712(13)00229-4

doi:10.1016/j.ijid.2013.07.002

© 2013 International Society for Infectious Diseases. Published by Elsevier Inc. All rights reserved.

-

-------